Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03912220 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT03912220: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03912220 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03912220, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study will evaluate the effects of a nutritional supplement called nicotinamide riboside in preventing small fiber nerve degeneration that is experimentally induced by applying capsaicin to skin in otherwise healthy study participants. Furthermore, the effects on nerve regeneration will also be evaluated. The results will be compared to a placebo control drug.
Interventions
- DRUG Nicotinamide riboside
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03912220
The ClinicalTrials.gov registry entry for NCT03912220 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotinamide riboside is the first listed.
NCT03912220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03912220 about?
NCT03912220 is a clinical study titled "Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration". This study will evaluate the effects of a nutritional supplement called nicotinamide riboside in preventing small fiber nerve degeneration that is experimentally induced by applying capsaicin to skin in otherwise healthy study participants. Furthermore, the effects on nerve regeneration will also be...
What is the current status of trial NCT03912220?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-09-01. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT03912220?
The interventions under investigation include: Nicotinamide riboside (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03912220?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.